The second clinical case presents a patient with ROS1 fusion-positive advanced NSCLC who achieved partial response on ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.

The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced ...

Non–small cell lung cancer (NSCLC), a malignancy that forms in the tissues of the lungs, accounts for the majority of lung ...

Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...

Zipalertinib showed a 35% overall response rate in EGFR exon 20 mutated NSCLC, with notable CNS activity and a favorable safety profile. NeoADAURA trial highlighted the feasibility of neoadjuvant EGFR ...

A new pill has kept lung-cancer patients free of the disease after surgery in a major clinical trial, offering a fresh option ...

The two main categories for lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Large cell lung cancer (LCLC) is a type of NSCLC. While the conditions share some ...

It's natural to feel afraid after a lung cancer diagnosis. But there's also real reason for hope, as treatment for lung cancer has improved dramatically in the last decade. (DigitalVision/Getty Images ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...